Status:
COMPLETED
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABI-H3733 in Healthy Adults
Lead Sponsor:
Assembly Biosciences
Conditions:
Chronic Hepatitis B
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
This study is designed to assess safety, tolerability, pharmacokinetics (PK), formulation (liquid and solid oral forms) and food effect of ABI-H3733 in healthy participants. Part 1 includes evaluation...
Eligibility Criteria
Inclusion
- No clinically significant abnormal findings on physical exam, medical history, or clinical laboratory results at screening.
Exclusion
- Positive test results for human immunodeficiency virus (HIV) or hepatitis B or C.
- History of or current persistent drug or alcohol abuse.
Key Trial Info
Start Date :
May 17 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 14 2021
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04271592
Start Date
May 17 2020
End Date
January 14 2021
Last Update
January 27 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Auckland Clinical Studies
Auckland, New Zealand